MedPath

FDA Grants First-Ever Clearance for Pediatric Functional Dyspepsia Treatment to NeurAxis's IB-Stim

• NeurAxis has received FDA 510(k) clearance for IB-Stim to treat Functional Abdominal Pain associated with Functional Dyspepsia and related nausea symptoms in patients aged 8-21 years.

• This represents the first-ever FDA-cleared treatment for functional dyspepsia, potentially doubling NeurAxis's addressable market while utilizing existing reimbursement infrastructure.

• IB-Stim uses Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, offering a non-surgical alternative in a therapeutic area with no FDA-approved drug treatments for children.

NeurAxis, Inc. announced today that it has received FDA 510(k) clearance for its IB-Stim device to treat Pediatric Functional Abdominal Pain (FAP) associated with Functional Dyspepsia (FD) and FD-related nausea symptoms in patients aged 8 to 21 years. This milestone marks the first treatment ever cleared or approved by the FDA specifically for functional dyspepsia.
The clearance represents the second expanded FDA indication for IB-Stim, following its initial approval for Functional Abdominal Pain associated with Irritable Bowel Syndrome (IBS). According to company officials, this new indication is expected to nearly double NeurAxis's total addressable market.
"This latest FDA clearance represents a pivotal milestone in NeurAxis' growth strategy," said Brian Carrico, President and Chief Executive Officer of NeurAxis. "Expanding into the treatment of Pediatric Functional Dyspepsia pain that includes related nausea symptoms, not only broadens our clinical impact but also positions us to drive significant revenue growth through a capital-efficient rollout."

Addressing an Unmet Medical Need

Functional dyspepsia is a chronic condition characterized by upper abdominal pain or discomfort, often accompanied by symptoms such as early satiety, fullness, and nausea. In pediatric patients, these symptoms can lead to significant complications.
Dr. Adrian Miranda, Chief Medical Officer of NeurAxis, explained the severity of the condition: "Functional dyspepsia can cause severe abdominal pain and nausea, and in adolescents, it often leads to serious secondary issues like fear of eating, weight loss, and significant dietary restriction. We are thrilled by the agency's decision, which gives us the opportunity to offer real hope to thousands of patients and their families who have had limited options—until now."
The lack of FDA-approved drug therapies for children with abdominal pain-related disorders of gut-brain interaction (DGBIs) has been a significant challenge in pediatric gastroenterology. Currently available pharmacologic treatments are used off-label, often with serious side effects and limited evidence of efficacy.

IB-Stim Technology and Implementation

IB-Stim utilizes Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, a non-surgical approach that delivers gentle electrical impulses to cranial nerve bundles in the ear. This neuromodulation therapy aims to address the underlying neurological components of functional gastrointestinal disorders.
The commercial rollout for this expanded indication will begin immediately, with NeurAxis leveraging existing infrastructure. The company noted that the indication will use the same CPT code, insurance coverage, and provider call points as the existing IBS indication, supporting a seamless and capital-efficient go-to-market strategy.
Further strengthening the commercial outlook, the American Medical Association recently approved a new CPT Category I code for IB-Stim, which will take effect in January 2026. This development, along with expanding insurance coverage, indicates growing acceptance of the technology among healthcare providers and payers.

Market Impact and Future Directions

As a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, NeurAxis is positioning itself as a leader in non-invasive, pediatric-focused treatments. The company is currently conducting additional clinical trials of PENFS technology in multiple pediatric and adult conditions with significant unmet healthcare needs.
The expansion into functional dyspepsia treatment represents a significant advancement in pediatric gastroenterology, offering a non-pharmacological option for a condition that affects thousands of children and adolescents. For patients and families who have struggled with limited treatment options, IB-Stim may provide a new approach to managing chronic abdominal pain and associated symptoms.
With this FDA clearance, NeurAxis continues to build on its foundation of evidence-based medicine and innovative technology, potentially transforming the treatment landscape for pediatric functional gastrointestinal disorders.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Expands Luminopia's Digital Therapeutic Approval for Amblyopia Treatment to Children Aged 8-12

Luminopia's VR-based digital therapeutic for amblyopia has received FDA clearance for children aged 8-12 years, expanding from its previous 4-7 year age indication based on robust real-world evidence.
The treatment offers a novel binocular approach using modified TV content through VR headsets, showing comparable efficacy in pre-teens as in younger children—the first such approval for this age group in over 20 years.

FDA Grants Orphan Drug Designation to NeuroNOS for Phelan-McDermid Syndrome Treatment

NeuroNOS's lead therapy BA-102 receives FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a rare genetic disorder linked to Autism Spectrum Disorder with no current FDA-approved treatments.
The designation provides significant development incentives including seven years of market exclusivity, tax credits for clinical trials, and FDA application fee waivers.

Spinogenix's SPG601 Shows Promise in Phase 2 Trial for Fragile X Syndrome

Spinogenix's SPG601 demonstrated a significant reduction in high-frequency gamma band activity, an EEG abnormality associated with Fragile X syndrome (FXS).
The Phase 2 trial met its primary endpoint, suggesting SPG601's potential to improve brain activity related to learning and memory in FXS patients.

Solid Biosciences' SGT-212 Receives FDA IND Clearance for Friedreich's Ataxia Gene Therapy Trial

The FDA has cleared Solid Biosciences' IND for SGT-212, a gene therapy targeting both neurological and cardiac manifestations of Friedreich's ataxia.
SGT-212 utilizes a dual route of administration, delivering full-length frataxin to the cerebellum via IDN infusion and to the heart via IV infusion.

FDA Approves PTC Therapeutics' Kebilidi, First Gene Therapy Dosed Directly into the Brain

The FDA has approved Kebilidi (eladocagene exuparvovec), a gene therapy by PTC Therapeutics, for aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder.
Kebilidi is the first gene therapy approved in the U.S. that involves direct administration into the brain, offering a novel approach to treating AADC deficiency.

NeurAxis Receives Expanded FDA Clearance for IB-Stim in Abdominal Pain Relief

NeurAxis has secured an expanded FDA 510(k) clearance for its IB-Stim device, a non-implanted nerve stimulator, to broaden its application in functional abdominal pain relief.
The expanded clearance increases the addressable market for IB-Stim by approximately 75% and allows for the use of up to four devices per patient, according to NeurAxis.

NeurAxis' IB-Stim Receives FDA Clearance for Functional Abdominal Pain, Expanding Market

NeurAxis received FDA 510(k) clearance for IB-Stim, a non-implanted nerve stimulator, for functional abdominal pain relief, expanding its market by approximately 75%.
The new clearance allows for the use of four IB-Stim devices per patient, potentially increasing device utilization and revenue for NeurAxis.

NeurAxis' IB-Stim Receives FDA Clearance for Expanded Use in Pediatric IBS

NeurAxis received FDA 510(k) clearance for IB-Stim, expanding its market by approximately 75%.
The clearance extends the age range for IB-Stim use from 11-18 to 8-21 years old, broadening access.

FDA Grants Breakthrough Therapy Designation to Sanbexin Sublingual Tablets for Acute Ischemic Stroke

Simcere Pharmaceuticals' Sanbexin sublingual tablets receive Breakthrough Therapy designation from the FDA for acute ischemic stroke (AIS) treatment.
The designation is based on Phase III clinical trial data demonstrating significant improvements in neurological recovery and independent living ability compared to placebo.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy